None
Skip to mainIndia is likely to approve Emergency Use Authorisation for the Merck drug Molnupiravir in a few days time. Molnupiravir is an oral drug designed to block the replication of various RNA viruses, including the SARS-CoV-2 virus. The medicine is meant for adults who are at risk for progressing to severe COVID-19 or hospitalization. The medicine can be taken at home.
Dr Ram Vishwakarma, Chairman of the Covid Strategy Group, CSIR calling the drugs the "final nail in the coffin of the virus by science", said, "I think Molnupiravir will be already available to us. Five companies are sitting with the drug manufacturer... I think any day we will have approval of Molnupiravir"
Five Indian pharmaceutical companies had partnered to conduct a clinical trial of Merck (MSD)’s experimental antiviral candidate Molnupiravir to treat mild Covid-19 in an outpatient setting. The partners are Cipla, Dr Reddy’s Laboratories, Sun Pharmaceutical Industries and Torrent Pharmaceuticals.
Molnupiravir works by disrupting the virus’s reproduction. Once the virus gets inside the body’s cells, it replicates its genome, which is made not of DNA but RNA (ribonucleic acid). These replicated genomes are then formed into complete virus particles which burst out of the cell and continue to spread around the body. However, the molecules of molnupiravir are absorbed by virus-infected cells, where they are converted into a defective version of the building blocks of RNA. So, when the virus tries to replicate, the resulting virus particles have defective genetic material and can no longer reproduce. This means that the viral load should remain low, which reduces the risk of serious disease.
In India, it might initially cost "2000 to 3000 or 4000 rupees per cycle of treatment, then it will come down to 500 to 600 or 1,000 rupees.
🕑 21 Oct, 2024 08:52 PM
Finance Ministry order on July 2024 DA enhancement
🕑 16 Oct, 2024 09:57 PM
Cabinet approves 3% DA hike from July 2023.
🕑 11 Oct, 2024 07:19 PM
Wait for DA hike cabinet approval getting longer
🕑 11 Oct, 2024 07:14 PM
Government Announces New NPS Contribution Guidelines for CG Employees
🕑 11 Oct, 2024 07:02 PM
PM directs action against non-performing or corrupt government employees
🕑 11 Oct, 2024 11:12 AM
Ad-hoc Bonus for 2023-24 for Central Government employees announed
🕑 10 Oct, 2024 05:35 PM
8th Pay Commission may reintroduce DA merger to Basic Pay at 50%
🕑 04 Oct, 2024 09:59 AM
Rate of Interest on GPF and similar funds for Oct-Dec, 2024
🕑 04 Oct, 2024 09:52 AM
Cabinet approves Productivity Linked Bonus for 78 days to railway employees
🕑 04 Oct, 2024 10:05 AM
PFRDA introduces Balanced Life Cycle Fund option
🕑 08 Aug, 2024 11:46 AM
RBI Keeps Key Interest Rate Unchanged to Tackle Inflation
🕑 23 Jun, 2024 08:47 AM
8th Pay Commission: How much pay hike central govt employees expect?
🕑 20 Jun, 2024 05:59 PM
Finance Minister May Increase Income Tax Exemption in Budget 2024
🕑 18 Jun, 2024 03:34 PM
The Impact and Expectations Surrounding the 8th Central Pay Commission
🕑 07 Jun, 2024 10:13 AM
Indian Members of Parliament: Compensation and Benefits
🕑 10 Apr, 2024 08:35 AM
Kendriya Vidyalaya Sangathan Admission Guidelines 2024-2025
🕑 05 Apr, 2024 01:23 PM
Kendriya Vidyalaya Balvatika Admission Schedule - 2024-25
🕑 02 Apr, 2024 09:25 AM
Kendriya Vidyalaya Admissions Open for 2024-25: Key Dates & Appln Process